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population values of pharmacokinetic parameters along with
their variabilities (7, 8, 19).
Stavudine (d4T; 29,39-didehydro-39-deoxythymidine) is a pyrimidine nucleoside antiretroviral agent with in vitro activity
against HIV similar to that of zidovudine (2). It also appears to
retain activity against some zidovudine-resistant strains of HIV
(16). Preclinical and clinical studies have also shown stavudine
to be less cytotoxic than zidovudine (1, 5); however, the doselimiting toxicity in humans is peripheral neuropathy (6, 18, 21).
This report summarizes the population pharmacokinetics of
stavudine in 81 patients to whom stavudine was administered
orally (p.o.) in phase I and phase I/II dose-ranging studies by
using nonlinear mixed-effects modeling as implemented in the
program NONMEM.

Nucleoside antiretroviral therapy currently remains the cornerstone of drug therapy of human immunodeficiency virus
(HIV) infection. Unfortunately, most of the currently available
agents exhibit significant interpatient variability in their pharmacokinetic properties, which leads to variability in in vivo
drug exposure (11). This can result in modulation of the therapeutic as well as the toxicological responses to these agents (3,
4, 9, 13). For example, the development of opportunistic infections and hematological toxicity has been linked to the
mean concentrations of zidovudine in serum (4, 13), and suppression of p24 antigen and changes in children’s intelligence
quotient scores have been correlated with didanosine exposure
(3, 9). Careful consideration of the pharmacokinetic properties
of drugs and elucidation of the sources of variability are important early in the dose-defining process for future testing in
large-scale clinical trials.
Recent emphasis in drug development has been placed on
population-based methods for describing the dispositions of drugs
in patients. Nonlinear mixed-effects modeling (NONMEM) and
nonparametric expectation maximization algorithm (NPEM)
are examples of techniques that allow for the estimation of

MATERIALS AND METHODS
Patients. Data from three phase I and phase I/II protocols of stavudine were
obtained from Bristol-Myers Squibb; the clinical results from those studies have
been described elsewhere (6, 18, 20). The patients enrolled in the protocols were
$12 years of age and had either AIDS as defined by the Centers for Disease
Control and Prevention (CDC) or AIDS-related complex (ARC; CDC stage
IV-A or IV-C-2), a CD4 cell count of #500/mm3, no active AIDS-defining
opportunistic infections, and no previous hematological intolerance to zidovudine. In addition to the above, patients had the following characteristics at the
time of entry into the study: hemoglobin concentration of $8.5 g/liter; neutrophil
count of $950/mm3; platelet count of $75,000/mm3; alanine aminotransferase,
aspartate aminotransferase, alkaline phosphatase, and bilirubin levels less than
three times the upper limit of normal; and a serum creatinine level of #1.5 mg/dl.
All patients gave informed consent according to the guidelines of the respective
institutions.
Study design. The allocation of 81 patients among the different regimens of
stavudine in the three protocols is provided in Table 1. Capsules of stavudine for
p.o. administration were administered to patients in dosages ranging from 0.1 to
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(401) 456-6590.
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The population pharmacokinetics and bioavailability of oral stavudine (d4T; 2*,3*-dideoxy-3*-deoxythymidine) was determined in 81 patients with AIDS or AIDS-related complex (ARC) enrolled in phase I and phase
I/II dose-ranging trials. Each patient underwent inpatient pharmacokinetic studies following administration of
the first oral stavudine dose; 59 patients were restudied after chronic therapy for an average of 19 days.
Thirty-three of these patients also received a single intravenous stavudine dose prior to starting an oral
regimen. A two-compartment model with first-order absorption and elimination was used as the structural
pharmacokinetic model. A basic model provided the following population parameter estimates (interpatient
variability expressed in parentheses as percent coefficient of variation): clearance/bioavailability 5 30.9
(24.5%) liters/h; volume of distribution/bioavailability 5 8.42 (not modeled) liters; volume of distribution at
steady state/bioavailability 5 68.9 (105%) liters; intercompartmental clearance/bioavailability 5 12.4 (26%)
liters/h; and first-order absorption rate constant 5 1.32 (78.9%) liters/h. In the subset of 33 patients receiving
both intravenous and oral doses, the bioavailability of stavudine was estimated to be 99.1% (18.5%). Total body
weight, stage of disease (AIDS versus ARC), and an oral stavudine dose of >200 mg were found to have a
statistically significant but a clinically marginal effect on the estimate of the oral clearance of stavudine. This
analysis shows the high degree of bioavailability of stavudine in patients with AIDS and ARC and the relatively
low degree of interpatient variability in oral drug clearance compared with those of other nucleosides.
Population pharmacokinetic analysis is a useful tool for assessing the combined effects of several patient
variables on the pharmacokinetic properties of drugs in human immunodeficiency virus-infected patients.
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TABLE 1. Stavudine dosage regimens for 81 patients included in
population pharmacokinetic analysis
Oral
dosage
(mg/kg/
day)

12
8
4
2
1
0.5
0.1
a

No. of patients-regimen by study sitea
Providence

New York

6-TID
5-QID
6-TID
6-QID
6-TID
4-BID, 4-QID
1-BID, 6-TID 2-BID, 5-QID
5-BID
3-BID
4-BID
4-BID

Multicenter

3-TID
5-TID
6-TID

Total no. of
patients (no. of
patients receiving
single i.v. dose)

11 (9)
12 (1)
14 (4)
17 (3)
8 (8)
13 (8)
6 (0)

BID, twice daily; TID, three times daily; QID, four times daily.

TABLE 2. Characteristics of 81 patients in population
pharmacokinetic analysis of stavudine given p.o.
Characteristica

Value

No. of men/womenb .............................................................. 71/7
Median age (yr [range]) ....................................................... 36 (22–85)
Median total body weight (kg [range]) .............................. 70 (41–102)
Median lean body weight (kg [range])c .............................. 70 (30–87)
Risk group (no. of patients)b
IVDU.................................................................................. 15
Sexual contact .................................................................... 56
Race (no. of patients)b
White .................................................................................. 61
Black...................................................................................... 6
Hispanic ................................................................................ 9
Disease stage (no. of patients)
AIDS ................................................................................... 26
ARC .................................................................................... 50
Unknown............................................................................... 5
Median initial CD4 cell no. (cells/mm3 [range]) ............ 153 (9–580)
Prior zidovudine therapy (no. of patients) ........................ 44
GI disease (no. of patients)d................................................ 16
Tobacco use (no. of patients).............................................. 30
Stavudine p.o. dose $200 mg (no. of patients) ................ 11
Development of peripheral neuropathy (no. of
patients).................................................................................. 34
a

IVDU, intravenous drug use; GI, gastrointestinal.
Data not available for some patients.
c
Calculated as 50 kg 1 2.3 z (height [in inches] 2 60) for men; 5 kg is
subtracted from this value for women.
d
Nonhepatobiliary, noncirrhotic; mainly diarrhea.
b
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12 mg/kg of body weight per day divided into two, three, or four doses per day.
The combined data set represented more than a 100-fold range in daily dosages
of stavudine that were fractionated into administration two, three, or four times
daily. A single intravenous (i.v.) dose was also given to a subset of patients prior
to the p.o. administration of stavudine, thus allowing for estimation of the
absolute bioavailability (F) in these patients.
All blood samples were collected as part of pharmacokinetic studies. Pharmacokinetic studies were conducted in an inpatient setting after administration of
the first p.o. dose to all 81 patients. Repeat inpatient sampling for pharmacokinetic analysis was performed for 59 (73%) of these patients after a mean of 19
days (range, 8 to 59 days) of stavudine therapy. Thirty-three patients also received a single i.v. dose (one-quarter of the p.o. dose) prior to receipt of the first
p.o. dose of stavudine.
Patients were admitted to an inpatient unit the evening prior to administration
of the study doses of stavudine and fasted overnight until 2 h following administration of the morning study dose. Blood samples (3 ml) were collected from an
indwelling i.v. catheter before and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 h
after administration of a p.o. dose in all protocols and up to 12 or 24 h in the
phase I studies. The single i.v. dose was delivered via a constant-rate infusion
pump over 60 min; blood samples were drawn before the infusion and at 0.25,
0.5, 0.75, 1, 1.1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 h after the start of the infusion.
Blood samples were collected in potassium EDTA-containing Vacutainer tubes,
placed on ice, and centrifuged at 3,000 3 g at 48C within 1 h of collection. The
plasma was placed in screw-cap polypropylene tubes, and the tubes were stored
at 2908C.
Plasma stavudine concentrations in 71 patients were assayed by a previously
described high-pressure liquid chromatography (HPLC) method (14). The precision of the HPLC assay was ,9% (coefficient of variation 3 100%). In patients
receiving stavudine at dosages of #2 mg/kg/day, a more sensitive radioimmunoassay was used to assay the stavudine concentrations in plasma samples. The total
number of samples assayed by this method comprised ca. 10% of the total
number of samples. This assay used 10 ml of sample combined with 185 ml of total
of antibody and control plasma. The mixture was combined and was stored
overnight at 48C, and then 200 ml of 125I-labeled histamine-stavudine conjugate
was added. This mixture was refrigerated at 48C for 4 h; this was followed by the
addition of 1 ml of a 7.5% polyethylene glycol solution containing 1% goat
anti-rabbit gamma globulin. The samples were then centrifuged, and the supernatant was decanted and discarded. The remaining pellet was resuspended in
scintillation fluid to measure the radioactivity. The lower limit of quantitation of
the radioimmunoassay was 2.5 ng/ml (standard curve range, 2.5 to 100 ng/ml).
Accuracy (as the percent deviation of the nominal value) and precision (as the
percent coefficient of variation [CV]) for quality control samples were 5 and 8%,
respectively. Selected plasma samples were assayed by both HPLC and radioimmunoassay, and the results obtained by both methods were in agreement (data
not shown).
Data sets. A total of 1,742 plasma stavudine concentrations were divided into
two data sets. Data on the concentration of drug in plasma for all 81 patients
(1,326 plasma samples) following the administration of the first or multiple p.o.
doses comprised the p.o. data set. An average of 16.4 (range, 4 to 24) plasma
stavudine levels were contributed by each patient. A second data set (entitled the
i.v./p.o. data set) consisted of 826 plasma samples collected after the first i.v. and
p.o. (first and multiple) doses for a subset 33 patients who received a single i.v.
dose of stavudine prior to studies of the pharmacokinetics of stavudine administered p.o.
Plasma stavudine concentrations versus time and clinical and demographic
data were obtained from databases generated from case report forms supplied
by Bristol-Myers Squibb. Plasma stavudine concentrations less than the lower
limit of quantitation were not used in this analysis. The translator portion of
NONMEM (NM-TRAN) uses data in a specific format in which dosing events at
time zero are followed by observation events (i.e., plasma drug concentrations or
CD4 cell counts) at relative time points for each individual. The data obtained

from Bristol-Myers Squibb were merged with the dosing information and were
configured in the NM-TRAN format by using a microcomputer for input into
NONMEM.
Pharmacostatistical model. Nonlinear mixed-effects modeling was performed
by using NONMEM version 3.0 (double precision, level 1.2) on an International
Business Machines ES-9000 computer (19). This version uses the first-order
approximation in generating function evaluations. Program-supplied PRED routines were used. Preliminary runs of several models established that a twocompartment open model with first-order rate constants (Ka’s) for absorption
and elimination (ADVAN4 TRANS3) was optimal for describing the data. The
structural model was parameterized as follows: p.o. clearance divided by F
(CL/F); volumes of distribution of the central compartment and at steady-state
both divided by F (V1/F and Vss/F, respectively); intercompartmental clearance
divided by F (Q/F); and Ka. Since previous pharmacokinetic studies have shown
that the half-life of stavudine is approximately 1.1 h (12), steady-state conditions
were assumed to exist in those patients undergoing repeat pharmacokinetic
studies following the administration of multiple doses. The same structural
model with a separate term for bioavailability (F1) was used for the subset of 33
patients who received both the i.v. and the p.o. formulations of stavudine.
Models for interpatient variability and residual error terms were determined
by changes in objective function and the increased precision of the pharmacokinetic parameter estimates. Interpatient variability in CL/F, Vss/F, Q/F, and Ka
were modeled by using a constant coefficient of variation (proportional) term, or
uj 5 u9j(1 1 huj), where uj is the estimate or typical value for a pharmacokinetic
parameter in the jth individual, u9j is the predicted pharmacokinetic parameter,
and huj represents the random difference (with mean 5 0 and variance 5 s2)
between the true value of the pharmacokinetic parameter for the individual and
the value predicted by the pharmacostatistical model.
Since a wide range of stavudine concentrations was observed, the residual
error was modeled as having both constant and proportional elements: Cij 5
[Cij(1 1 ε2ij)] 1 ε2ij, where Cij is the observed concentration in serum for the jth
individual at time i, C9ij is the model-predicted concentration in serum for the jth
individual at time i, and ε1ij and ε2ij are components of residual error. This design
allowed for the model to be additive at low drug concentrations and proportional
at higher concentrations. Fits that used models in which residual error was
strictly proportional, additive, or exponential were inferior (data not shown).
Model-building procedure. The minimum value of the objective function (22
3 log likelihood) along with plots of weighted residuals versus predicted concentrations in plasma aided in determination of the appropriate pharmacostatistical models for analysis of the data. After the basic model was constructed,
additional fixed effects (i.e., patient characteristics or variables) were introduced
into the model on the basis of the selection of variables or outcomes of clinical
importance and previous observations with nucleoside antiretroviral agents. Absolute values for patient-specific variables such as total body weight or CD4
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TABLE 3. Population pharmacokinetic parameters of stavudine by using a basic model in 81 patients (p.o. data set)
Model parameter

Population estimate
95% CI
Interpatient variabilitya
95% CI
a
b

CL/F
(liters/h)

V1/F
(liters)

Vss/F
(liters)

Q/F
(liters/h)

Ka
(liters/h)

ε1

ε2

30.9
28.5, 33.3

8.42
4.44, 12.4

68.9
44.7, 93.1

12.4
6.94, 17.9

1.32
1.07, 1.57

0.17
0.13, 0.21

0.002
0, 0.003

24.5
17, 30

NMb

105
32, 145

26
0, 45

78.9
63, 92

CV (in percent).
NM, not modeled.

RESULTS
The characteristics of the 81 patients included in the analysis
are given in Table 2. The population consisted largely of white
men in their mid-30s who acquired HIV through homosexual
or heterosexual transmission. Most patients had ARC, with the
median CD4 cell count being less than 200 cells per mm3 upon
entry into the study. Approximately half of the patients had
received previous zidovudine therapy for various intervals. The
range of measurable plasma stavudine concentrations ranged
between 0.0025 and 7.5 mg/ml.
Basic model. The pharmacokinetic parameter estimates obtained with the basic model are given in Table 3. The CL of
stavudine given p.o. was estimated to be ;31 liters/h, with
interpatient variability estimated to be 24.5%. The decline in
plasma stavudine concentrations as described by a two-compartment model was evident by estimation of a peripheral
compartment (represented by Vss/F 2 V1/F) about sevenfold

larger than that of the central compartment. The absorption
rate of stavudine given p.o. was typically rapid, with a high
estimate for interpatient variability. Interpatient variability
(expressed as percent CV) for Vss/F and Q/F were 105 and
26%, respectively. The CV for residual error was estimated to
be ;41% for the range of plasma stavudine concentrations
measured.
Results of the analysis of data for the subset of 33 patients
who received stavudine both i.v. and p.o. (i.v./p.o. data set) are
given in Table 4. The estimate of absolute F was 99.1%, with an
interpatient variability of 18.5% (CV). When all data for the
patients who received stavudine by the p.o. and i.v. routes were
analyzed together (i.e., levels in plasma of all 81 patients given
drug by the i.v. and p.o. routes), the estimate of F was similar
to this value (data not shown). The estimates of CL and Vss for
this subset of patients were similar to those obtained with the
full (p.o.) data set. Estimates of V1 and Q (after accounting for
F) were different for this subset of 33 patients compared with
those for all 81 patients, likely because of improved estimation
of values for these parameters with the availability of plasma
samples collected during the i.v. infusion.
Model building. The patient characteristics and variables
(fixed effects) tested individually for inclusion in the model of
CL/F for the p.o. data set are given in Table 5. The fixed effects
found singly to significantly influence the estimates of CL/F
were p.o. stavudine doses of $200 mg, total body weight, a
diagnosis of AIDS, receipt of prior zidovudine therapy, and
calculated lean body weight. However, the 95% CIs for the
magnitude of the effect for the latter two factors included the
null value. Models that used different stavudine dose breakpoints (e.g., $150 mg) had no effect on estimates of CL. Therefore, only a p.o. stavudine dose of $200 mg, total body weight,
and a diagnosis of AIDS versus ARC were tested further in the
full model.
The fixed effects found to significantly influence the estimates of Vss/F were total body weight and calculated lean body
weight. Although statistically significant, the 95% CI for estimates of the magnitude of the effect of lean body weight
included the null value (as it did with the CL of drug given
p.o.), and therefore it was not included in the full model.

TABLE 4. Population pharmacokinetic parameters for subset of 33 patients who received stavudine both i.v. and p.o. (i.v./p.o. data set)
Model parameter

Population estimate
95% CI
Interpatient variabilitya
95% CI
a
b

CV (in percent).
NM, not modeled.

F
(% of dose)

CL
(liters/h)

V1
(liters)

Vss
(liters)

Q
(liters/h)

Ka
(liters/h)

ε1

ε2

99.1
82.3, 116

34.6
28.9, 40.3

23.9
18.8, 29.0

56.1
47.3, 64.9

20.3
16.3, 24.3

2.38
1.8, 3.0

0.13
0.09, 0.17

0.003
0, 0.006

18.5
1, 36

20.6
0, 43

NMb

NM

48
0, 71

103
31, 175
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count (which reflects the degree of disease progression) were included in the
model as follows: TVCL 5 TVCL 1 uj z TBW, where TVCL is the typical value
of CL/F, TBW is the total body weight, and uj is the factor value for each
individual with a known total body weight.
Nominal data describing patient characteristics and categories were fashioned
with if-then statements; for example, the effect of oral stavudine doses greater
than 200 mg on CL/F would be coded as follows: if mg $200 then TVCL 5
TVCL z u1, where absolute oral doses of $200 mg result in a different estimation
of CL/F for patients receiving large oral doses.
The criterion for acceptance of a factor into the model was a decrease in the
minimum value of the objective function of .3.8 following introduction of a
single term (degrees of freedom 5 1), and it was considered statistically significant at the 5% (P , 0.05) level by using the x2 distribution (17, 19). A fixed effect
was retained in the model as a weight on a particular variable if the minimum
objective function decreased significantly and if the 95% confidence intervals
(CIs) for the estimate did not include the null value. If the minimum objective
function decreased significantly but the 95% CI for the estimate included the null
value, the effect of the variable was considered to be of borderline significance
and it was not retained in the final model. Plots of weighted residuals versus
predicted concentrations in plasma or variables also guided the selection of fixed
effects for inclusion and retention in the model during the model-building procedure.
Single variables that were found to significantly improve the fit of the model to
the data were tested together to develop the final model. In order to eliminate
covariates, each variable was taken out of the model by setting it equal to its null
value. A change in the minimum objective function of .3.8 signified that the
variable was important and it was retained in the final model.
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TABLE 5. Summary of analyses of the effects of single patient variables on stavudine population pharmacokinetic parameters by using the
p.o. data seta
Null value

Do the following affect CL/F?
High dosed
TBW
AIDS
Prior ZDV therapy
LBM
Smoking
GI diseasee
Age
Starting CD4 cell no.
Development of PN

1
0
1
1
0
1
1
0
1
1

Do the following affect Vss/F?
TBW
LBM
Age

0
0
0

Factor value (95% CI)b

Change in MOFc

P value

Conclusion

1.41 (1.18, 1.64)
0.17 (0.04, 0.3)
1.23 (1.01, 1.45)
1.12 (0.9, 1.34)
0.05 (20.03, 0.13)
0.93 (0.74, 1.12)
0.94 (0.54, 1.35)
0.01 (20.22, 0.25)
0.99 (0.75, 1.23)
0.99 (0.76, 1.22)

241.17
232.72
219.47
27.83
26.91
23.11
21.19
20.06
20.02
20.12

,0.001
,0.001
,0.001
,0.01
,0.01
.0.05
.0.2
.0.3
.0.3
.0.3

Test in full model
Test in full model
Test in full model
Borderline effect
Borderline effect
No effect
No effect
No effect
No effect
No effect

0.689 (0.207, 1.17)
20.589 (21.399, 0.221)
20.076 (20.706, 0.554)

25.34
210.616
20.04

,0.05
,0.01
.0.3

Test in full model
Borderline effect
No effect

a
MOF, minimum objective function; TBW, total body weight (in kilograms); ZDV, zidovudine; LBM, lean body mass (in kilograms); GI, gastrointestinal; CD4, CD4
cell count (in cells per cubic millimeter); PN, peripheral neuropathy.
b
When the null value is equal to 1, the factor is a multiplier of CL/F; when the null value is equal to 0, the factor is a multiplier on the variable tested.
c
Relative to basic model.
d
Dose of $200 mg of stavudine given p.o.
e
Nonhepatobiliary, noncirrhotic; mainly diarrhea.

Final model. The parameter estimates generated in the final
model are given in Table 6. The final model included terms for
total body weight, stage of HIV infection (AIDS versus ARC),
and receipt of a high dose ($200 mg per dose) of stavudine.
Figure 1 shows the plasma stavudine concentrations in a 70-kg
patient with AIDS or ARC. Total body weight in the estimation of Vss/F was dropped from the full model because its effect
became statistically insignificant when all factors were included
in the final model for CL/F. When the parameters for high p.o.
stavudine doses, total body weight, and AIDS were individually
restricted to their null values, significant increases (141, 25, and
13, respectively) in the minimum objective function resulted.
Therefore, all three fixed effects were retained within the final
model for the CL of stavudine given p.o.: CL/F 5 (18.8 1
0.13 z TBW) z (1.2 2 stage) z (1.5 2 dose), where CL/F is in
liters per hour, TBW is total body weight in kilograms, stage is
0.2 if the patient has ARC and 0 if the patient has AIDS, and
dose is 0.5 if the patient ingests a p.o. dose of ,200 mg and 0
if the patients ingests a p.o. dose of $200 mg. The estimates of
V1/F, Vss/F, Q/F, and Ka and their respective CIs were essentially unchanged from those from the basic model, as were the
estimates of interpatient variability. Residual error was also

unchanged from that from the basic model. A comparison of
the plots of weighted residuals versus predicted plasma stavudine concentrations in the basic and final models showed some
improvement for the predicted plasma stavudine concentrations in the higher range (Fig. 2).
DISCUSSION
Therapy of HIV infection with currently available nucleoside antiretroviral agents is frequently frustrated by a high
degree of variability between patients in in vivo drug exposure
following the administration of fixed doses of drug. This is
particularly problematic for zidovudine, for which there may
be more than a 10-fold range in the area under the concentration-time curve among patients because of differences in the F
and CL of the drug (11). The differences in drug exposure may
have a marked impact on the observed antiviral effects, as well
as the tolerance to drug during therapy (9–11). Therefore,
development of newer nucleosides with improved F and a low
degree of interpatient variability would be desirable in the
long-term management of patients with HIV infection.
The present study extends previous observations concerning

TABLE 6. Population pharmacokinetic parameters for 81 patients given stavudine p.o. for final model with p.o. data set
Model parameter

Population estimate
(95% CI)

Interpatient variabilityb
95% CI

CL/F (liters/h)

[18.8 (11.6, 26) 1
0.13 (0.03, 0.24) z
TBW] z [1.2 (1.0,
1.38) 2 stage] z
[1.5 (1.12),
1.86) 2 dose]
20
11, 25

V1/F (liters)

Vss/F (liters)

Q/F (liters/h)

Ka (liters/h)

ε1

ε2

8.18 (4.68, 11.7)

70 (44.9, 95.2)

13.1 (7.7, 18.5)

1.35 (1.13, 1.57)

0.17 (0.13, 0.21)

0.002 (0, 0.003)

NMc

89
24, 123

30
0, 46

82
67, 94

a
CL/F 5 [18.8 1 0.13 z TBW] z [1.2 2 stage] z [1.5 2 dose], where TBW is total body weight, stage is equal to 0.2 if the patient has ARC and 0 if the patient has AIDS,
and dose is equal to 0.5 if the patient ingests p.o. dose of ,200 mg and 0 if the patient ingests $200 mg.
b
CV (in percent).
c
NM, not modeled.
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the pharmacokinetics of stavudine in patients with HIV infection. The estimate for typical systemic F of stavudine in 33
patients was nearly 100%. A previous estimate of F in six
patients receiving 4-mg/kg oral doses (data for these patients
were also included in this population analysis) averaged 82%
(12). Since i.v. and p.o. dose studies were performed on different days, drug CL is assumed to be stable over the period of
study to allow for an estimation of F; changes in drug CL
between days would result in erroneous values for drug F.
Previous comparisons of stavudine pharmacokinetic parameters following administration of the first and multiple p.o.
doses showed no changes in the CL of drug given p.o. (12).
However, since the i.v./p.o. data set comprised all pharmacokinetic data after p.o. administration (i.e., first and steady-state
study doses) as well as pharmacokinetic data after i.v. administration for these patients, we also estimated the F of stavudine for these 33 patients using pharmacokinetic data from the
first p.o. and i.v. doses only; since these studies were done
within 1 day of each other, the possibility of changes in drug
CL between days would be highly remote. The estimate of F
with this stripped i.v./p.o. data set was still approximately 100%
(data not shown).
This analysis identified patient characteristics associated
with the population estimate of CL of drug given p.o. Information on total body weight, the diagnosis of AIDS (versus
ARC), and p.o. stavudine doses of $200 mg statistically improved the population model for CL/F (see final model). The
increase in stavudine CL/F with the higher dose is consistent
with trends reported previously and suggests a slightly lower F
of drug given p.o. at higher doses. Reduction in the F values of
certain nucleosides given p.o. has previously been attributed to
saturation of carrier-mediated transport of drug across the
gastrointestinal mucosa (10, 11, 15).

Although inclusion of some fixed effects resulted in a statistically significant improvement in the model, it appears that
some of these associations are of limited clinical significance.
The change in the CL of stavudine given p.o. with higher doses
is of limited clinical importance since dose-limiting peripheral
neuropathy precludes the use of daily exposures associated
with this dose, and lower doses have been shown to have
acceptable tolerance with clinical benefit (20). The difference
in CL/F between patients with AIDS and those with ARC was
small. As shown in Fig. 1, there is much overlap between the
serum stavudine concentrations was for typical patients with
either AIDS or ARC. Similarly, the effect that total body
weight had on stavudine CL/F was of small magnitude; only a
15% variation in the base value of the CL of drug given p.o.
(calculated by using the median total body weight of 70 kg for
the 81 patients) occurred for the upper and lower extremes of
the total body weight in patients enrolled in these studies.
These data suggest that stavudine doses do not need to be
adjusted for total body weight in adult patients weighing between 40 and 100 kg. However, in patients with AIDS with a
combination of extreme values in body weight, dose individualization may be required to achieve maximal antiviral effects.
This analysis represents one of the most comprehensive
evaluations of the pharmacokinetics of an antiretroviral agent
in target populations prior to widespread use of the drug. The
results show that intersubject variability in the major pharmacokinetic parameters for stavudine that influence systemic exposure (i.e., CL of drug given p.o. and the area under the
concentration-time curve) is low. Low variability in CL/F between patients suggests that dose is an acceptable controller
for exposure to stavudine in vivo. Further studies to evaluate
stavudine pharmacokinetics over more prolonged periods of
therapy are in progress.
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FIG. 1. Simulated plasma stavudine concentration-versus-time curves for a 70-kg patient with ARC or AIDS receiving a 40-mg dose of oral stavudine. Curves were
derived from a simulation with 100 patients by using the population values of the pharmacokinetic parameters from the final model and their estimated variances and
covariances (i.e., lower triangle of the covariance matrix). Bold lines indicate mean levels in plasma at 0.5, 1, 1.5, 2, 3, 4, 5, 6, and 8 h postdose from the simulation
for patients with AIDS (— - — -) or ARC (——). The corresponding upper and lower 95% CIs for stavudine levels in the plasma of patients with AIDS (dashed lines)
or ARC (dotted lines) are also shown.
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